Table 3 Symptom improvement of participants.
N = 39 | Group | Baseline | After treatment | P-value |
|---|---|---|---|---|
GERD-Q | LAF& ESO | 12.0 (11.0, 14.0) | 8.0 (5.0, 10.0) | < 0.001 |
ESO | 11.5 (10.3, 12.0) | 8.5 (5.3, 11.8) | 0.010 | |
RDQ | LAF& ESO | 13.0 (9.0, 18.0) | 9.0 (5.0, 12.0) | 0.001 |
ESO | 16.5 (10.0, 19.0) | 12.5 (7.0, 14.8) | 0.004 | |
RSI | LAF& ESO | 6.0 (4.0, 14.0) | 3.0 (2.0, 6.0) | < 0.001 |
ESO | 6.0 (4.0, 13.0) | 5.0 (2.3, 8.0) | 0.002 | |
Heartburn -daytime | LAF& ESO | 7.0 (0.0, 20.0) | 0.0 (0.0, 8.0) | 0.005 |
ESO | 12.0 (0.0, 27.0) | 0.5 (0.0, 12.0) | 0.001 | |
Heartburn -nighttime | LAF& ESO | 8.0 (0.0, 24.0) | 2.0 (0.0, 10.0) | < 0.001 |
ESO | 12.0 (0.3, 28.0) | 2.0 (0.0, 12.0) | 0.004 | |
Regurgitation -daytime | LAF& ESO | 6.0 (2.0, 15.0) | 2.0 (0.0, 8.0) | 0.014 |
ESO | 8.0 (0.0, 23.0) | 4.0 (0.0, 12.0) | 0.008 | |
Regurgitation -nighttime | LAF& ESO | 8.0 (2.0, 21.0) | 2.0 (0.0, 6.0) | < 0.001 |
ESO | 10.0 (0.0, 27.0) | 3.0 (0.0, 11.0) | < 0.001 |
